Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy

• Published in: European journal of pharmacology 2008-09, Vol.591 (1-3), p.136-141
• Main Authors: Knauer, Christopher S, Campbell, Jeffrey E, Galvan, Betsy, Bowman, Christopher, Osgood, Sarah, Buist, Susan, Buchholz, Lisa, Henry, Brian, Wong, Erik H F, Shahid, Mohammed, Grimwood, Sarah
• Format: Article
• Language: English
• Subjects: Animals; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - metabolism; Antipsychotic Agents - pharmacokinetics; Brain - metabolism; Dose-Response Relationship, Drug; Fluorobenzenes - administration & dosage; Fluorobenzenes - metabolism; Fluorobenzenes - pharmacokinetics; Humans; Male; Piperidines - administration & dosage; Piperidines - metabolism; Piperidines - pharmacokinetics; Positron-Emission Tomography - methods; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A - metabolism; Serotonin Antagonists - administration & dosage; Serotonin Antagonists - metabolism; Serotonin Antagonists - pharmacokinetics; Tissue Distribution
• ISSN: 0014-2999
• DOI: 10.1016/j.ejphar.2008.06.063

An in vivo binding assay is characterized for [(3)H]M100907 binding to rat brain, as a measure of 5-HT(2A) receptor occupancy. Dose-response analyses were performed for various 5-HT(2A) antagonist reference agents, providing receptor occupancy ED(50) values in conjunction with plasma and brain concentration levels. Ketanserin and M100907 yielded dose-dependent increases in 5-HT(2A) receptor occupancy with ED(50)s of 0.316 mg/kg and 0.100 mg/kg, respectively. The atypical antipsychotics risperidone, olanzapine, and clozapine dose-dependently inhibited in vivo [(3)H]M100907 binding with ED(50) values of 0.051, 0.144, and 1.17 mg/kg, respectively. In contrast, the typical antipsychotic haloperidol exhibited only 20.1% receptor occupancy at 10 mg/kg despite producing dose-dependent increases in plasma and brain exposure levels. The novel psychopharmacologic agent asenapine dose-dependently occupied 5-HT(2A) receptors in rat brain with an ED(50) of 0.011 mg/kg, demonstrating higher 5-HT(2A) receptor potency compared with the other atypical antipsychotics tested. This enhanced potency was supported by a lower plasma exposure EC(50) of 0.477 ng/ml, compared with risperidone (1.57 ng/ml) and olanzapine (7.81 ng/ml) and was confirmed in time course studies. The validated [(3)H]M100907 rat in vivo binding assay allows for preclinical measurement of 5-HT(2A) receptor occupancy, providing essential data for understanding the pharmacological profile of novel antipsychotic agents. Additionally, the corresponding plasma and brain drug exposure data analyses provides a valuable data set for 5-HT(2A) reference agents by enabling direct comparison with any complementary studies performed in rats, thus providing a foundation for predictive pharmacokinetic/pharmacodynamic models and, importantly, allowing for translation to human receptor occupancy studies using [(11)C]M100907 positron emission tomography.